Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Policy / Regulatory

China’s NMPA Suspends Daewoong Bio’s Antibiotic, Excludes Firm from National Procurement Program

Fineline Cube Jul 25, 2024

The National Medical Products Administration (NMPA) in China has taken a decisive step to suspend...

Company Drug

Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Cleared for Clinical Trial by NMPA

Fineline Cube Jul 25, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Drug

Hinova Pharmaceuticals Receives NMPA Approval to Test Myelofibrosis Drug Candidate HP560

Fineline Cube Jul 25, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biopharmaceutical company based in Chengdu, has announced that it...

Company Drug

Belief BioMed and Takeda’s Hemophilia B Gene Therapy BBM-H901 Accepted for NMPA Review

Fineline Cube Jul 25, 2024

Belief BioMed Group (BBM), a Shanghai-based gene therapy specialist, and Takeda have announced that the...

Company Deals

Pinetree Therapeutics Strikes EGFR Degrader Deal with AstraZeneca Worth Over USD 500 Million

Fineline Cube Jul 25, 2024

Pinetree Therapeutics Inc., a Massachusetts-based biotechnology company, has announced the signing of an exclusive option...

Company Deals

Novartis Partners with Dren Bio to Develop Next-Generation Cancer Therapies

Fineline Cube Jul 25, 2024

Novartis (NYSE: NVS), a leading Swiss pharmaceutical company, has entered into a strategic collaboration with...

Company Drug

Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study

Fineline Cube Jul 25, 2024

Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the...

Company Drug

Novo Nordisk’s Wegovy Approved in the UK to Reduce Cardiovascular Risks in Overweight Adults

Fineline Cube Jul 24, 2024

Novo Nordisk (NYSE: NVO)’s anti-obesity drug Wegovy (semaglutide) has received a new indication approval in...

Company Drug

IASO Biotherapeutics’ CAR-T Therapy Fucaso Receives FDA IND Approval for Multiple Sclerosis

Fineline Cube Jul 24, 2024

China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...

Company Drug

ST Phi Therapeutics’ Universal Cell Therapy for Solid Tumors Gets Green Light for Clinical Trial in China

Fineline Cube Jul 24, 2024

ST Phi Therapeutics, a Hangzhou-based cell therapy specialist, has secured tacit approval from China’s National...

Company

Shanghai Rightongene Biotechnology Co., Ltd Executives Under Investigation by Chinese Authorities

Fineline Cube Jul 24, 2024

Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a Chinese biopharmaceutical company, has announced that key...

Company Medical Device

Hangzhou Jianjia Medical’s Arthbot Surgical Robot Receives NMPA Approval for Orthopedic Procedures

Fineline Cube Jul 24, 2024

Hangzhou Jianjia Medical Technology Co., Ltd has received marketing approval from China’s National Medical Products...

Company Drug

Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China

Fineline Cube Jul 24, 2024

Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical...

Company

BeiGene Launches Flagship US Facility in New Jersey to Expand Oncology R&D and Manufacturing

Fineline Cube Jul 24, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a global biotechnology company, has announced the inauguration...

Company Drug

Bayer’s BAY 3375968 Receives NMPA Approval for Clinical Trial in Advanced Solid Tumors

Fineline Cube Jul 24, 2024

Bayer AG (ETR: BAYN), a multinational pharmaceutical giant based in Germany, has received clinical trial...

Company Drug

Chipscreen’s HDAC Inhibitor Chidamide to be Tested in Combination Therapy for CRC by NMPA

Fineline Cube Jul 24, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has received...

Company Deals

Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328

Fineline Cube Jul 24, 2024

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received...

Company Deals

Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies

Fineline Cube Jul 24, 2024

Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally,...

Company Deals

Shanghai Desano and Chongqing Kangfude Partner to Establish Peptide Drug Production Base in China

Fineline Cube Jul 24, 2024

Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...

Company Deals

TowardPi Medical Partners with OCULUS Iberia to Introduce Advanced OCTA Technology to Spain

Fineline Cube Jul 24, 2024

TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company specializing in ophthalmic imaging, has...

Posts pagination

1 … 320 321 322 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.